TherapeuticsMD, Inc. (TXMD)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
TherapeuticsMD, Inc. (TXMD) trades at $2.31 with AI Score 62/100 (Hold). TherapeuticsMD, Inc. is a women's healthcare company focused on prescription pharmaceutical and prenatal vitamin products. Market cap: $26.74M, Sector: Healthcare.
Last analyzed: Feb 5, 2026TherapeuticsMD, Inc. (TXMD) Healthcare & Pipeline Overview
TherapeuticsMD, Inc. pioneers women's health with innovative therapies like IMVEXXY, BIJUVA, and ANNOVERA, alongside a comprehensive prenatal vitamin line, addressing critical needs in a growing market and demonstrating a strong commitment to women's wellness and reproductive health.
Investment Thesis
TherapeuticsMD presents a notable research candidate due to its focus on the underserved women's health market. The company's existing product portfolio, including IMVEXXY, BIJUVA, and ANNOVERA, addresses significant unmet needs in menopause management and contraception. With a gross margin of 96.6%, the company demonstrates efficient operations. The company's pipeline of preclinical projects offers potential for future growth and revenue diversification. The company's current P/E ratio is 86.23 and the market cap is $0.03B. This investment thesis hinges on the successful commercialization of existing products and the advancement of its pipeline, driving revenue growth and increased market share in the women's health sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Gross Margin of 96.6% indicates efficient cost management and strong pricing power.
- Profit Margin of 10.8% demonstrates profitability in a competitive pharmaceutical market.
- Market Cap of $0.03B suggests potential for growth as the company expands its product portfolio and market reach.
- P/E Ratio of 86.23 reflects investor expectations of future earnings growth.
- The company's focus on women's health addresses a large and growing market with unmet needs.
Competitors & Peers
Strengths
- Portfolio of approved women's health products.
- High gross margin.
- Established distribution network.
- Focus on unmet needs in women's health.
Weaknesses
- Small market capitalization.
- Dependence on a limited number of products.
- Intense competition in the pharmaceutical industry.
- Pending stock data update.
Catalysts
- Results from clinical trials of preclinical projects.
- Expansion of ANNOVERA sales and market share.
- Increased adoption of BIJUVA for vasomotor symptoms.
- Growth in prenatal vitamin sales through expanded distribution.
Risks
- Regulatory setbacks for preclinical projects.
- Competition from new entrants in the women's health market.
- Dependence on key products for revenue generation.
- Economic factors affecting consumer spending on healthcare.
- Product liability claims related to pharmaceutical products.
Growth Opportunities
- Expansion of ANNOVERA Market Share: ANNOVERA, a novel contraceptive vaginal system, represents a significant growth opportunity for TherapeuticsMD. The global contraceptive market is projected to reach $40 billion by 2028. By increasing awareness and adoption of ANNOVERA, TherapeuticsMD can capture a larger share of this market. This involves targeted marketing campaigns, partnerships with healthcare providers, and expansion of distribution channels. The timeline for significant market share gains is estimated at 2-3 years.
- Advancement of Preclinical Pipeline: TherapeuticsMD's pipeline of preclinical projects, including TX-005HR, TX-006HR, TX-007HR, TX-008HR, and TX-009HR, offers substantial growth potential. These projects target unmet needs in hormone replacement therapy and contraception. Successful development and commercialization of these products could generate significant revenue streams. The timeline for bringing these products to market varies, but initial clinical trials could begin within the next 1-2 years.
- Increased Sales of Prenatal Vitamins: TherapeuticsMD manufactures and distributes a range of branded and generic prescription prenatal vitamins. The prenatal vitamin market is driven by increasing awareness of the importance of maternal nutrition. By expanding its marketing and distribution efforts, TherapeuticsMD can increase sales of its prenatal vitamin products. This involves partnerships with healthcare providers, online marketing campaigns, and expansion into new retail channels. The timeline for increased sales is estimated at 1 year.
- Strategic Partnerships and Acquisitions: TherapeuticsMD can pursue strategic partnerships and acquisitions to expand its product portfolio and market reach. This could involve partnering with other pharmaceutical companies to co-develop or co-market products, or acquiring companies with complementary technologies or product lines. Strategic partnerships and acquisitions can accelerate growth and diversification. The timeline for such opportunities is variable and depends on market conditions.
- Geographic Expansion: TherapeuticsMD currently operates primarily in the United States. Expanding into international markets represents a significant growth opportunity. This could involve partnering with international distributors or establishing a direct presence in key markets. Geographic expansion can increase revenue and diversify risk. The timeline for international expansion is estimated at 3-5 years, depending on regulatory approvals and market entry strategies.
Opportunities
- Expansion of ANNOVERA market share.
- Advancement of preclinical pipeline.
- Increased sales of prenatal vitamins.
- Strategic partnerships and acquisitions.
Threats
- Regulatory changes and pricing pressures.
- Competition from generic drug manufacturers.
- Product liability claims.
- Economic downturn affecting consumer spending.
Competitive Advantages
- Proprietary formulations and patents for key products.
- Established brand reputation in the women's health market.
- Distribution network with wholesale and retail pharmacies.
- Pipeline of preclinical projects for future growth.
About TXMD
TherapeuticsMD, Inc., founded in 2008 and headquartered in Boca Raton, Florida, is a women's healthcare company dedicated to developing and commercializing innovative prescription pharmaceutical products and prenatal vitamins. The company's portfolio includes IMVEXXY, a vaginal estrogen therapy for the treatment of moderate-to-severe dyspareunia (painful sexual intercourse) due to menopause; BIJUVA, a bio-identical hormone therapy combining 17ß-estradiol and progesterone for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause; and ANNOVERA, a novel, ring-shaped vaginal system providing reversible contraception for up to one year. In addition to its marketed products, TherapeuticsMD has a pipeline of preclinical projects focused on developing innovative hormone therapies, including transdermal creams, transdermal patches, and oral formulations. These projects aim to address unmet needs in women's health, such as hormone replacement therapy and contraception. The company also manufactures and distributes a range of branded and generic prescription prenatal vitamins under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 brands, catering to the nutritional needs of women before, during, and after pregnancy. TherapeuticsMD sells its products to wholesale distributors and retail pharmacy distributors throughout the United States, ensuring broad access to its therapies and vitamins.
What They Do
- Develop and commercialize prescription pharmaceutical products for women's health.
- Offer IMVEXXY for the treatment of moderate-to-severe dyspareunia.
- Provide BIJUVA, a bio-identical hormone therapy for vasomotor symptoms.
- Market ANNOVERA, a ring-shaped contraceptive vaginal system.
- Develop preclinical projects for hormone therapies.
- Manufacture and distribute branded and generic prescription prenatal vitamins.
- Sell products to wholesale distributors and retail pharmacy distributors.
Business Model
- Develop, manufacture, and market prescription pharmaceutical products.
- Generate revenue through sales of prescription drugs and prenatal vitamins.
- Distribute products through wholesale and retail pharmacy channels.
- Invest in research and development to expand product portfolio.
Industry Context
TherapeuticsMD operates within the specialty and generic drug manufacturing industry, a segment characterized by intense competition and evolving regulatory landscapes. The women's health market, in particular, is experiencing growth driven by an aging population and increasing awareness of hormonal health and contraception options. TherapeuticsMD competes with established pharmaceutical companies and generic drug manufacturers. The company differentiates itself through its focus on innovative therapies and its portfolio of branded and generic prenatal vitamins. The industry is subject to stringent regulatory requirements and pricing pressures, requiring companies to demonstrate clinical efficacy and cost-effectiveness.
Key Customers
- Women seeking treatment for menopausal symptoms.
- Women seeking contraception options.
- Pregnant and breastfeeding women requiring prenatal vitamins.
- Wholesale distributors of pharmaceutical products.
- Retail pharmacies.
Financials
Chart & Info
TherapeuticsMD, Inc. (TXMD) stock price: $2.31 (+0.00, +0.00%)
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Sep 21, 2023
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Feb 22, 2022
-
Stocks That Hit 52-Week Lows On Friday
benzinga · Jan 14, 2022
-
12 Health Care Stocks Moving In Monday's After-Market Session
· Dec 6, 2021
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TXMD.
Price Targets
Wall Street price target analysis for TXMD.
MoonshotScore
What does this score mean?
The MoonshotScore rates TXMD's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
TherapeuticsMD, Inc. Healthcare Stock: Key Questions Answered
What does TherapeuticsMD, Inc. do?
TherapeuticsMD, Inc. is a women's healthcare company that develops, manufactures, and commercializes prescription pharmaceutical products and prenatal vitamins. Their product portfolio includes treatments for menopausal symptoms (IMVEXXY and BIJUVA) and contraception (ANNOVERA). Additionally, they manufacture and distribute branded and generic prescription prenatal vitamins. The company sells its products through wholesale distributors and retail pharmacies, focusing on addressing unmet needs in women's health and providing comprehensive solutions for various stages of a woman's life.
Is TXMD stock worth researching?
TXMD stock presents a speculative investment opportunity with both potential upside and significant risks. The company's focus on the women's health market and its portfolio of approved products offer growth potential. However, the small market capitalization and dependence on a limited number of products create vulnerability. Investors should carefully consider the company's financial performance, pipeline development, and competitive landscape before investing. The high gross margin of 96.6% is a positive indicator, but the overall financial health and future prospects require thorough evaluation.
What are the main risks for TXMD?
The main risks for TXMD include regulatory setbacks for preclinical projects, intense competition from generic drug manufacturers, and dependence on key products for revenue generation. Regulatory changes and pricing pressures could also negatively impact the company's profitability. Additionally, product liability claims and economic factors affecting consumer spending on healthcare pose potential threats. Investors should be aware of these risks and carefully assess their potential impact on the company's financial performance and future prospects.
What are the key factors to evaluate for TXMD?
TherapeuticsMD, Inc. (TXMD) currently holds an AI score of 62/100, indicating moderate score. Key strength: Portfolio of approved women's health products. Primary risk to monitor: Regulatory setbacks for preclinical projects. This is not financial advice.
How frequently does TXMD data refresh on this page?
TXMD prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven TXMD's recent stock price performance?
Recent price movement in TherapeuticsMD, Inc. (TXMD) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Portfolio of approved women's health products. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider TXMD overvalued or undervalued right now?
Determining whether TherapeuticsMD, Inc. (TXMD) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying TXMD?
Before investing in TherapeuticsMD, Inc. (TXMD), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Stock data pending update, which may impact financial metrics and valuation analysis.